身体组成特征与克罗恩病抗TNF治疗应答相关并可能提供替代给药方案
该队列研究纳入2007年1月至2012年6月间106例未接受过抗TNF治疗的克罗恩病患者,用CT估算身体组成参数,分析其与抗TNF原发无应答和继发性失应答的关系。中位随访3年,原发无应答26例(24.5%),继发失应答29例(27.4%);多因素分析显示肌少症与原发无应答相关(OR 2.93;1.28-6.71,P=.01),免疫调节剂治疗与继发失应答降低相关(OR 0.48;0.23-0.98,P=.04),BMI与去脂体重相关性差(r2=0.15,P=.54)。
要点
- 肌少症与原发无应答独立相关(OR 2.93;1.28-6.71,P=.01)。
- 免疫调节剂治疗与继发失应答降低相关(OR 0.48;0.23-0.98,P=.04)。
- BMI与去脂体重相关性差(r2=0.15,P=.54),肌少症可能影响给药。
核心结论
- 在该队列研究中,身体组成特征与BMI相关性不佳;肌少症与原发无应答相关,可能对给药有潜在影响,并可作为药代动力学失败的一种解释。
研究设计与样本
- 队列研究,纳入2007年1月至2012年6月间106例未接受过抗TNF治疗的克罗恩病患者,接受抗TNF治疗,用CT扫描分析身体组成参数以估算去脂体重;采用COX回归分析3年随访数据。
主要发现
- 106例中26例(24.5%)原发无应答,29例(27.4%)继发失应答。
- 单因素分析中,原发无应答与低白蛋白(OR 0.94;0.88-0.99,P=.04)及肌少症(OR 4.69;1.83-12.01,P=.001)相关,分析时考虑了患者药物治疗、疾病严重程度和身体组成。
- 多因素分析中,肌少症与原发无应答相关(OR 2.93;1.28-6.71,P=.01)。
- 免疫调节剂治疗与继发失应答降低相关(OR 0.48;0.23-0.98,P=.04)。
- BMI与去脂体重相关性差(r2=0.15,P=.54)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-tumour necrosis factor (TNF)s form a major part of therapy in Crohn's disease and have a primary nonresponse rate of 10%-30% and a secondary loss of response rate of 5% per year. Myopenia is prevalent in Crohn's disease and is measured using body composition analysis tools. AIM: To test the hypothesis that body composition can predict outcomes of anti-TNF primary nonresponse and secondary loss of response. METHODS: Between January 2007 and June 2012, 106 anti-TNF naïve patients underwent anti-TNF therapy for Crohn's disease with body composition parameters analysed using CT scans to estimate body fat-free mass. The outcome measures were primary nonresponse and secondary loss of response. COX-regression analysis was used with 3 year follow-up data. RESULTS: A total of 106 patients were included for analysis with 26 (24.5%) primary nonresponders and 29 (27.4%) with secondary loss of response to anti-TNF therapy. Sex-specific cut-offs for muscle and fat were ascertained by stratification analysis. On univariate analysis, primary nonresponse was associated with low albumin (OR 0.94; 0.88-0.99, P = .04) and presence of myopenia (OR 4.69; 1.83-12.01, P = .001) when taking into account patient's medical therapy, severity of disease and body composition. On multivariate analysis, presence of myopenia was associated with primary nonresponse (OR 2.93; 1.28-6.71, P = .01). Immunomodulator therapy was associated with decreased secondary loss of response (OR 0.48; 0.23-0.98, P = .04). BMI was poorly correlated with lean body mass (r2 = 0.15, P = .54). CONCLUSIONS: In this cohort study, body composition profiles did not correlate well with BMI. Myopenia was associated with primary nonresponse with potential implications for dosing and serves as an explanation for pharmacokinetic failure.
引用
- Ding NS, Malietzis G, Lung PFC, et al. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther. 2017. PMID: 28881017. doi:10.1111/apt.14293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。